growth of 4.6 percent, over-year, following the 4.9 percent growth seen in the first quarter. The expansion was driven largely by exports and tourism, which benefited from trade partners’ brighter economic

7,698 mn, up by 5.2% YoY with a 6% YoY growth in net profit to THB 2,483 mn. Establishment of a Joint Venture to support business expansion plan On 5 September 2017, the Company established a new joint

unit in a government hospital to provide hemodialysis services (The nd branch) that still has focused on continuous expansion of dialysis unit. On the past 29th September, 2017 the subsidiary

slower rate in March and reached its bottom in April (-8.1% YoY), it made a v-shape recovery with 18.0% growth in June, partly driven by additional supply of C-Vitt from capacity expansion. - While Q2’20

network expansion led to increasing cost of service 3.9%YoY and 3.4%QoQ; however, SG&A was well-managed and dropped -12%YoY and -8.8%QoQ, resulted in stabilized EBITDA with -0.9%YoY and +1.6%QoQ. Net profit

such information to the Stock Exchange of Thailand. Reasons and Justifications for the Transaction : The Company has a plan for business expansion, and it is thus necessary for the Company to use more

”) Retail Finance 100% General characteristics of transactions: 1. AEONTS provides the support on the business operation including marketing research and support as well as system support to ACS Capital, and

last year. Selling and administrative expenses (including research and development – R&D) in Q1’19 went up 16.7% from Q1’18 and keep close to Q4’18 due to the R&D and sales force invested in order to

year and 23.0% in last quarter this year. Selling and administrative expenses (including research and development – R&D) in Q2’19 went up 21.0% from Q2’18 and up 5.8% from Q1’19 due to R&D and sales

drop to 19.1%, compare to 24.5% in the same quarter of last year and 19.9% in last quarter. Selling and administrative expenses (including research and development – R&D) in Q3’19 went up 5.7% from Q3’18